Sarepta Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Great. Good afternoon, everyone. I'm Maneka Mirchandaney from the Evercore ISI biotech team. I am really pleased to be here with Sarepta. We've got Doug Ingram, who's its President and CEO; and Ian Esteban, who's SVP, Chief of Staff and Corporate Affairs. Thank you both so much for being here today. And Doug, to start -- just give us a broad sense for where Sarepta is now? And what the vision is for the next few years?
Questions & Answers
Sure. Thank you very much, and thanks for having us today. I mean if I started -- its most -- its broadest sense. We have to consider the fact we're a rare disease company focused on genetic medicine to treat disease and bring a better life to patients. There are 7,000 rare diseases that exist. 80% of them are single-gene mutations, which means they are really prime candidates for the intervention of genetic medicine. As we sit here today, only 5% of those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
